KLOW

What is KLOW?

KLOW is a catalog item that supplies the three GLOW components and the tripeptide KPV together in one vial. Each component keeps its own chemistry, cited studies and regulator records, listed below. We supply KLOW as a lyophilized vial for in-vitro laboratory research only.

What does a KLOW vial contain?

KLOW supplies GHK-Cu, BPC-157, TB-500 and KPV together in one vial. The single compounds are listed separately; the amount of each in the vial is shown on the product options.

• GHK-Cu: copper-binding tripeptide complex (C14H23CuN6O4+, 402.92 Da, CAS 89030-95-5).
• BPC-157: synthetic pentadecapeptide (C62H98N16O22, 1419.5 Da, CAS 137525-51-0).
• TB-500: thymosin beta 4 (43 residues) (C212H350N56O78S, 4963.4 Da, CAS 77591-33-4).
• KPV: tripeptide, C-terminal fragment of alpha-MSH (C16H30N4O4, 342.4 Da, CAS 67727-97-3).

What does published research on KLOW cover?

KLOW combines compounds we also list on their own, so no study covers this exact vial. Each component has its own studies, checked in PubMed on 5 October 2026. One cited study per component follows.

• GHK-Cu: GHK binds copper(II) with an affinity similar to the copper transport site on albumin, and the complex is called GHK-Cu. (Pickart, J Biomater Sci Polym Ed, 2008; PMID 18644225)
• BPC-157: In cultured rat tendon cells BPC 157 was examined for effects on tendon outgrowth, cell survival and cell migration. (Chang et al., J Appl Physiol (1985), 2011; PMID 21030672)
• TB-500: Thymosin beta 4 is described as the main G-actin sequestering peptide in mammalian tissue and as a mediator of cell migration, proliferation and differentiation. (Philp et al., FASEB J, 2003; PMID 14500546)
• KPV: In a mouse model of crystal-induced peritonitis KPV was compared with alpha-MSH, a core melanocortin peptide and a melanocortin receptor 3 and 4 agonist. (Getting et al., J Pharmacol Exp Ther, 2003; PMID 12750433)

Mechanism, every cited study and the regulator records are on the KLOW page of the research library. Papers are listed by what they measured, not as evidence of any use.

How is KLOW supplied and stored?

KLOW is supplied as a co-lyophilized (freeze-dried) powder in a sealed vial, for in-vitro laboratory research only. Our stated storage condition for the sealed lyophilized vial is 2 to 8 °C. The label and the lot certificate carry the lot-specific storage condition and expiry date.

What is the regulatory status of KLOW?

KLOW combines research compounds we also list on their own. It is not a medicinal product. Regulator records are listed per component.

GHK-Cu: The EMA medicines database (checked 5 October 2026) lists no centrally authorised medicine naming GHK-Cu (searched as prezatide or copper tripeptide) as an active substance. National authorisations are not in that dataset.

BPC-157: The EMA medicines database (checked 5 October 2026) lists no centrally authorised medicine naming BPC-157 (searched as BPC) as an active substance. National authorisations are not in that dataset.

TB-500: The EMA medicines database (checked 5 October 2026) lists no centrally authorised medicine naming TB-500 (searched as thymosin beta or timbetasin) as an active substance. National authorisations are not in that dataset.

KPV: The EMA medicines database (checked 5 October 2026) lists no centrally authorised medicine naming KPV as an active substance. National authorisations are not in that dataset.

A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.

Which related research pages and compounds are listed?

• KLOW: chemistry, literature and regulatory status
• How to read a certificate of analysis

Components in the catalog:

• GHK-Cu
• BPC-157
• TB-500
• KPV